Taxol

(paclitaxel)

ApprovedSmall molecule

Paclitaxel is a chemotherapy drug used to treat various cancers including breast cancer, ovarian cancer, and lung cancer by stopping cancer cells from dividing and growing.[2] Taxol is currently approved and in use across 219 indications[4].[1]

Taxol is one of 2139 small molecule programs targeting Glioma. It is currently in Approved.

219

Indications

2,221

Total Trials

Active Trials

2,138

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Head and Neck CarcinomaActive, not recruiting

Small Cell CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Peritoneum CancerApproved

HyperplasiaActive, not recruiting

HIV InfectionActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Urinary Bladder CarcinomaApproved

MetastasisApproved

GliomaPhase 1

Active, not recruiting

Head and Neck CarcinomaPhase 2

Active, not recruiting

Small Cell CarcinomaPhase 1

Active, not recruiting

Pancreatic NeoplasmApproved

Active, not recruiting

Peritoneum CancerApproved

Approved

HyperplasiaPreclinical

Active, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Urinary Bladder CarcinomaApproved

Approved

MetastasisApproved

Approved

Showing 10 of 218 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Trodelvy

37 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Nubain

AAultman Health Foundation

Preclinical

1 7

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Pembrolizumab

NCT04652076

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT04253964

Phase 1Recruiting

Solid Cancers

NCT05403554

Q4 2026

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT05990127

Phase 3Recruiting

Cervical Cancer

NCT03534713

Phase 3Active, not recruiting

Cervical Cancer

NCT01566240

Clinical

Trials by Indication[1]

Breast Cancer36 trials

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05840211·654 enrolled

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 1/2·NCT02015676·69 enrolled

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00068757·23 enrolled

Show 33 more trials

Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Completed·UUniversity of Washington·Phase 2·NCT00194779·50 enrolled

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04090398·70 enrolled

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05177796

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT05929768·2,400 enrolled

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT00559845·56 enrolled

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Completed· Roche logo

Roche·Phase 1·NCT01918254·66 enrolled

MEtronomic TrEatment Option in Advanced bReast cAncer

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT02954055·140 enrolled

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT03199885·190 enrolled

A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

Withdrawn· Roche logo

Roche·Phase 4·NCT01156961

Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00270491·130 enrolled

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Completed· Roche logo

Roche·Phase 3·NCT01120184·1,095 enrolled

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT00645177·10 enrolled

Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer

Completed·—·Phase 2·NCT02263495·118 enrolled

Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer

Completed·—·Phase 2·NCT00006256·44 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

Completed·—·Phase 2·NCT02978495·154 enrolled

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Completed·GGeorge Albert Fisher·Phase 2·NCT00403130·31 enrolled

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Terminated· Amgen logo

Amgen·Phase 2·NCT00356681·282 enrolled

Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

Completed·UUniversity of Chicago·Phase 1·NCT00724386·26 enrolled

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Completed·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04224922·63 enrolled

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT03742102·243 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04895358·340 enrolled

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Not yet recruiting·DDavid Garcia Cinca·Phase 2·NCT04301375·27 enrolled

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT01617668·209 enrolled

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00482391·95 enrolled

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00052351

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT01008150·141 enrolled

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

Completed·TTheodoros Foukakis·Phase 2·NCT01722968·33 enrolled

Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer

Unknown status·TTheradex·Phase 3·NCT00025688

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Unknown status·RRenJi Hospital·Phase 3·NCT02879513·290 enrolled

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Active, not recruiting·PProvidence Health & Services·Phase 1/2·NCT02734290·29 enrolled

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Completed·GGeron Corporation·Phase 2·NCT01256762·166 enrolled

Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates

Completed·CCentro Nacional de Investigaciones Oncologicas CARLOS III·Phase 1/2·NCT01484080·140 enrolled

Non-Small Cell Lung Cancer26 trials

Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· AbbVie logo

AbbVie·Phase 1·NCT02944396·25 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04253964·105 enrolled

Show 23 more trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06692738·880 enrolled

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04989283

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Not yet recruiting·AAkeso·Phase 3·NCT05990127·642 enrolled

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT00547443

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01413750·23 enrolled

S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00002969·60 enrolled

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Completed·UUniversity of Miami·N/A·NCT01209520·6 enrolled

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003117·584 enrolled

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Terminated· Roche logo

Roche·Phase 2·NCT00434226·56 enrolled

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276588·46 enrolled

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003313·243 enrolled

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT00828009·70 enrolled

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00055887

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00563784·68 enrolled

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 2·NCT01507428·138 enrolled

Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer

Completed·VVanderbilt-Ingram Cancer Center·Phase 1·NCT00002519·6 enrolled

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

Terminated·WWest Virginia University·Phase 1·NCT02252796·1 enrolled

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT01560104·160 enrolled

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00042835·48 enrolled

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Completed· Roche logo

Roche·Phase 2·NCT01366131·104 enrolled

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00062179·7 enrolled

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 1·NCT01862081·80 enrolled

Ovarian Cancer13 trials

Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer

Unknown status·NNational University Hospital, Singapore·Phase 1·NCT02545010·24 enrolled

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00657878·215 enrolled

Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00660842·800 enrolled

Show 10 more trials

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02440425·42 enrolled

Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum

Unknown status·TTheradex·Phase 2·NCT00003160·100 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05636111·34 enrolled

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting· Suzhou Suncadia Biopharmaceuticals Co., Ltd. logo

Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT06394492·440 enrolled

Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer

Unknown status· GSK logo

GSK·Phase 2·NCT00003733·40 enrolled

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Completed· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 3·NCT04908787·421 enrolled

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT00945191·24 enrolled

Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer

Completed·UUniversity Medical Center Groningen·Phase 1·NCT02312661·15 enrolled

WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01144442·10 enrolled

Cervical Cancer10 trials

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Completed·GGOG Foundation·Phase 3·NCT01414608·926 enrolled

Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00057863·35 enrolled

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Recruiting·UUniversity Hospital, Toulouse·Phase 3·NCT03534713·310 enrolled

Show 7 more trials

Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer

Active, not recruiting·UUniversity College, London·Phase 3·NCT01566240·500 enrolled

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Not yet recruiting·GGuangzhou Gloria Biosciences Co., Ltd.·Phase 3·NCT05798819·424 enrolled

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04974944·172 enrolled

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Withdrawn·SSWOG Cancer Research Network·Phase 3·NCT00057928

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Completed·AAkeso·Phase 2·NCT04868708·50 enrolled

Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients

Unknown status·Xxie congying·Phase 3·NCT01756170·200 enrolled

Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00138151·33 enrolled

Fallopian Tube Cancer9 trials

Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT03462212·290 enrolled

Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03410784·72 enrolled

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Terminated·CCraig L Slingluff, Jr·Phase 2·NCT00373217·6 enrolled

Show 6 more trials

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191646·919 enrolled

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00814086·23 enrolled

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Unknown status·GGynecologic Oncology Group··NCT01366183·290 enrolled

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Unknown status·GGOG Foundation·Phase 3·NCT00108745·1,157 enrolled

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00079430·113 enrolled

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00063401·39 enrolled

69 more indications

Esophageal Cancer6 trials

Chemoradiation and Panitumumab for Esophageal Cancer

Completed·—·Phase 2·NCT01077999·78 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00021320·21 enrolled

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03281369·214 enrolled

Show 3 more trials

A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02898077·440 enrolled

Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00033657·97 enrolled

Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer

Unknown status·MMona Frolova·Phase 2·NCT03579004·48 enrolled

Gastric Cancer4 trials

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT00003298·39 enrolled

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01924533·525 enrolled

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Withdrawn·KKorean South West Oncology Group·Phase 2·NCT03766607

Show 1 more trial

Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis

Unknown status·SSeoul St. Mary's Hospital·Phase 1/2·NCT04943653·61 enrolled

Paclitaxel4 trials

Role of Curcumin in Paclitaxel Induced PN

Unknown status·—·Phase 2·NCT05966441·80 enrolled

Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001450·58 enrolled

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed·LLaekna Limited·Phase 2·NCT04374630·150 enrolled

Show 1 more trial

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Completed·—·Phase 2·NCT01853748·512 enrolled

Small Cell Lung Cancer4 trials

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02279732·342 enrolled

Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004055·38 enrolled

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04672928·20 enrolled

Show 1 more trial

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Withdrawn· Eli Lilly logo

Eli Lilly·Phase 2·NCT00768131

Advanced Solid Tumors3 trials

Study of INCB123667 in Subjects With Advanced Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05238922·604 enrolled

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04047862·446 enrolled

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Recruiting·FFate Therapeutics·Phase 1·NCT07216105·113 enrolled

Advanced Cancer3 trials

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003376·330 enrolled

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·NNYU Langone Health·Phase 1/2·NCT00004105

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT02305654·200 enrolled

Gastroesophageal Junction Cancer3 trials

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03760822·112 enrolled

APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers

Completed·AApexigen America, Inc.·Phase 2·NCT03165994·34 enrolled

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06251973·37 enrolled

Endometrial Cancer3 trials

A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients

Unknown status·KKorean Gynecologic Oncology Group·Phase 2·NCT00373620·50 enrolled

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Recruiting· GSK logo

GSK·Phase 2·NCT07108270·30 enrolled

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Unknown status·UUniversity of Manchester·Phase 2·NCT03570437·124 enrolled

Advanced Urothelial Cancer2 trials

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02256436·542 enrolled

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT03871036·53 enrolled

Gastric Adenocarcinoma2 trials

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Completed·SSamsung Medical Center·Phase 2·NCT02448329·26 enrolled

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT04034251·12 enrolled

Locally Advanced2 trials

Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00014599·31 enrolled

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT03694002·21 enrolled

Stage IV Ovarian Epithelial Cancer2 trials

Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer

Completed·AAGO Study Group·Phase 3·NCT00006454

High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery

Completed·EEBMT Solid Tumors Working Party·Phase 3·NCT00004921

Radiation Therapy2 trials

Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix

Completed·GGynecologic Oncology Group·Phase 1·NCT00003377·29 enrolled

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Completed·SSWOG Cancer Research Network·Phase 2·NCT00055835·7 enrolled

Germ Cell Tumor2 trials

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00072215·1 enrolled

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00423852·26 enrolled

Bladder Cancer2 trials

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Terminated·MMedical University of South Carolina·Phase 2·NCT00268450·21 enrolled

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Metastatic Prostate Cancer2 trials

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00028769·41 enrolled

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00049257·58 enrolled

Pembrolizumab2 trials

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

Completed·LLeap Therapeutics, Inc.·Phase 1·NCT02013154·151 enrolled

GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting·NNETRIS Pharma·Phase 1/2·NCT04652076·240 enrolled

Metastatic Melanoma2 trials

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Completed·PProf. Dr. med. Dirk Schadendorf·Phase 1/2·NCT02308553·33 enrolled

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 3·NCT01006252·336 enrolled

Metastatic Tumors2 trials

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Phase II Study for Solid Metastatic Tumors

Completed·NNYU Langone Health·Phase 2·NCT02474186·41 enrolled

Carboplatin2 trials

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Not yet recruiting·RRenJi Hospital·Phase 2·NCT07283692·46 enrolled

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Active, not recruiting·JJules Bordet Institute·Phase 1/2·NCT03616886·129 enrolled

Patients With Solid Tumors2 trials

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

Completed·RRoswell Park Cancer Institute··NCT00003569·2 enrolled

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT01301716·75 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03719924·106 enrolled

Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma

Completed·CChinese Academy of Medical Sciences·Phase 1/2·NCT02446574·33 enrolled

Primary Peritoneal Cancer2 trials

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNRG Oncology·Phase 3·NCT04095364·450 enrolled

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Terminated·UUConn Health·Phase 2·NCT00408070·5 enrolled

Thyroid Cancer1 trial

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00004089

Advanced Head and Neck Cancer1 trial

Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00003592·230 enrolled

Papilloma1 trial

De-Escalation Therapy for Human Papillomavirus Negative Disease

Completed·UUniversity of Chicago·Phase 2·NCT03944915·35 enrolled

Ovarian Epithelial Cancer1 trial

Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer

Terminated·GGynecologic Oncology Group·Phase 3·NCT00002819

PARP Inhibitor1 trial

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00516724·189 enrolled

Ovarian Tumor1 trial

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01357161·136 enrolled

Kidney Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003342·30 enrolled

Thoracic Tumors1 trial

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Recruiting· Amgen logo

Amgen·Phase 1·NCT06333951·500 enrolled

Chemotherapy1 trial

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

Recruiting·FFudan University·Phase 1/2·NCT06494943·27 enrolled

Advanced or Metastatic Solid Tumors1 trial

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00793897·21 enrolled

Cisplatin1 trial

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Completed·WWomen's Cancer Care Associates, LLC·Phase 3·NCT02501954·48 enrolled

Esophageal Adenocarcinoma1 trial

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Unknown status·—·Phase 2·NCT02037048·63 enrolled

Carcinosarcoma1 trial

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

Completed·UUniversity of Oklahoma·Phase 1·NCT03206177·26 enrolled

Renal Cancer1 trial

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Completed· Novartis logo

Novartis·Phase 1·NCT03798626·167 enrolled

Cervical Carcinoma1 trial

Indirect Comparison Topotecan Cervical Carcinoma

Completed· GSK logo

GSK··NCT01345279·1 enrolled

Microbiota1 trial

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

Not yet recruiting·FFundación GECP·Phase 2·NCT07247786·68 enrolled

Combination Therapy1 trial

Clinical Study of Decitabine and Paclitaxel Combination Therapy

Unknown status·DDong Wha Pharmaceutical Co. Ltd.·Phase 1·NCT03282825·18 enrolled

Gastric Carcinoma1 trial

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy

Completed·KKrankenhaus Nordwest·Phase 3·NCT01248403·300 enrolled

Intravenous1 trial

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

Completed· Bayer logo

Bayer·Phase 1·NCT02366949·75 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Completed·RRitu Salani·Phase 1·NCT01219777·9 enrolled

Cancer of Unknown Primary1 trial

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Unknown status·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT00003558·140 enrolled

Nasopharyngeal Carcinoma1 trial

Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT02250599·80 enrolled

Triple-Negative Breast Cancer1 trial

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05681728·26 enrolled

Adenocarcinoma1 trial

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT07284134·560 enrolled

NSCLC1 trial

Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC

Withdrawn·VVirginia Commonwealth University·Phase 1·NCT02059967

Abemaciclib1 trial

ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

Completed·MMedSIR·Phase 2·NCT04603183·162 enrolled

Advanced Malignancies1 trial

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT01325441·565 enrolled

Melanoma1 trial

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00976573·149 enrolled

Solid Cancers1 trial

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

Recruiting·LLight Chain Bioscience - Novimmune SA·Phase 1·NCT05403554·70 enrolled

Solid Tumors1 trial

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT01617928·12 enrolled

Neurotoxicity1 trial

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00517621·100 enrolled

Uterine Cancer1 trial

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

Terminated·—·N/A·NCT01367301·14 enrolled

Resectable NSCLC1 trial

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02259621·39 enrolled

Cancer of the Esophagus1 trial

Combination Chemotherapy Combined With Radiation Therapy in Treating Patients Who Have Stage II or Stage III Cancer of the Esophagus

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 1/2·NCT00008047

Metastatic Solid Tumors1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Efficacy and Safety1 trial

Completed·MMylan Inc.·Phase 3·NCT02472964·500 enrolled

Squamous Cell Carcinoma1 trial

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Recruiting·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 2·NCT06856213·65 enrolled

Clinical Trial1 trial

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Completed· Sanofi logo

Sanofi·Phase 3·NCT01593228·37 enrolled

Autologous Stem Cell Transplantation1 trial

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00231582·50 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01281150·22 enrolled

Serous Carcinoma1 trial

Papillary Serous Carcinoma of the Endometrium

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00515073·30 enrolled

Treatment1 trial

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Bone Marrow Transplantation1 trial

Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer

Terminated·LLouisiana State University Health Sciences Center Shreveport·Phase 1/2·NCT00003086·12 enrolled

Locally Advanced Head and Neck Cancer1 trial

Paclitaxel, Carboplatin and Radiotherapy as Induction Therapy in Locally Advanced Head and Neck Cancer

Completed·SSusanne Arnold·Phase 2·NCT00176254·40 enrolled

Head and Neck Cancers1 trial

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Completed·OOncolytics Biotech·Phase 3·NCT01166542·167 enrolled

Unspecified1 trial

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruiting· Roche logo

Roche·Phase 3·NCT03768063·1,000 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 29, 1992

TAXOL

NDA NDA020262

Jan 7, 2005

ABRAXANE

NDA NDA021660

Jul 27, 2022

PACLITAXEL

NDA NDA211875

May 11, 2023

PACLITAXEL

NDA NDA216338

Sources

References

[1]
ClinicalTrials.gov — 2221 trial records for paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Taxol drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216338). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Taxol. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Patent Landscape[6]

Patent Cliff

Aug 13, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8268348Feb 21, 2026

9101543Feb 21, 2026

7758891Feb 21, 2026

8034375Aug 13, 2026

8268348*PEDAug 21, 2026

9 more patents

9101543*PEDAug 21, 2026

7758891*PEDAug 21, 2026

8034375*PEDFeb 13, 2027

9597409Mar 4, 2032

9393318Mar 4, 2032

9393318*PEDSep 4, 2032

9597409*PEDSep 4, 2032

9511046Jan 12, 2034

9511046*PEDJul 12, 2034